{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:40:36Z","timestamp":1776069636060,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40268-026-00541-0","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:50:38Z","timestamp":1773859838000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions"],"prefix":"10.1007","volume":"26","author":[{"given":"Hegui","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"5","key":"541_CR1","first-page":"405","volume":"62","author":"K Winnicka","year":"2005","unstructured":"Winnicka K, Tomasiak M, Bielawska A. Piracetam\u2014an old drug with novel properties. Acta Pol Pharm. 2005;62(5):405\u20139.","journal-title":"Acta Pol Pharm"},{"issue":"4","key":"541_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000057700","volume":"13","author":"T Waegemans","year":"2002","unstructured":"Waegemans T, Wilsher CR, Danniau A, et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord. 2002;13(4):217\u201324. https:\/\/doi.org\/10.1159\/000057700.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"541_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-2003-39981","volume":"36","author":"R Uebelhack","year":"2003","unstructured":"Uebelhack R, Vohs K, Zytowski M, et al. Effect of piracetam on cognitive performance in patients undergoing bypass surgery. Pharmacopsychiatry. 2003;36(3):89\u201393. https:\/\/doi.org\/10.1055\/s-2003-39981.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"541_CR4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.athoracsur.2006.05.005","volume":"82","author":"I Szalma","year":"2006","unstructured":"Szalma I, Kiss A, Kardos L, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg. 2006;82(4):1430\u20135. https:\/\/doi.org\/10.1016\/j.athoracsur.2006.05.005.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"541_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11055-009-9109-7","volume":"39","author":"TT Batysheva","year":"2009","unstructured":"Batysheva TT, Bagir\u2019 LV, Kostenko EV, et al. Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders. Neurosci Behav Physiol. 2009;39(2):193\u20137. https:\/\/doi.org\/10.1007\/s11055-009-9109-7.","journal-title":"Neurosci Behav Physiol"},{"issue":"5","key":"541_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archneur.58.5.781","volume":"58","author":"M Fedi","year":"2001","unstructured":"Fedi M, Reutens D, Dubeau F, Andermann E, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol. 2001;58(5):781\u20136. https:\/\/doi.org\/10.1001\/archneur.58.5.781.","journal-title":"Arch Neurol"},{"issue":"4","key":"541_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000203788","volume":"96","author":"MA el- Hazmi","year":"1996","unstructured":"el-Hazmi MA, Warsy AS, al-Fawaz I, et al. Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematol. 1996;96(4):221\u20136. https:\/\/doi.org\/10.1159\/000203788.","journal-title":"Acta Haematol"},{"issue":"2","key":"541_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2710.2008.00901.x","volume":"33","author":"D Ince Gunal","year":"2008","unstructured":"Ince Gunal D, Agan K, Afsar N, et al. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients. J Clin Pharm Ther. 2008;33(2):175\u20138. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00901.x.","journal-title":"J Clin Pharm Ther"},{"issue":"1-2","key":"541_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000111493","volume":"25","author":"PC Wheble","year":"2008","unstructured":"Wheble PC, Sena ES, Macleod MR. A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovasc Dis. 2008;25(1\u20132):5\u201311. https:\/\/doi.org\/10.1159\/000111493.","journal-title":"Cerebrovasc Dis"},{"key":"541_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pediatrneurol.2023.08.003","volume":"148","author":"A Salamah","year":"2023","unstructured":"Salamah A, Darwish AH. Docosahexaenoic acid plus piracetam versus piracetam alone for treatment of breath-holding spells in children: a randomized clinical trial. Pediatr Neurol. 2023;148:32\u20136. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.08.003.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"541_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.genhosppsych.2012.05.009","volume":"35","author":"MG Rao","year":"2013","unstructured":"Rao MG, Holla B, Varambally S, et al. Piracetam treatment in patients with cognitive impairment. Gen Hosp Psychiatry. 2013;35(4):e1\u20132. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.05.009.","journal-title":"Gen Hosp Psychiatry"},{"key":"541_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108358","volume":"243","author":"FA Gouhie","year":"2024","unstructured":"Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. Cognitive effects of piracetam in adults with memory impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2024;243:108358. https:\/\/doi.org\/10.1016\/j.clineuro.2024.108358.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"541_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s0005-2736(02)00654-5","volume":"1609","author":"MP Mingeot-Leclercq","year":"2003","unstructured":"Mingeot-Leclercq MP, Lins L, Bensliman M, et al. Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta. 2003;1609(1):28\u201338. https:\/\/doi.org\/10.1016\/s0005-2736(02)00654-5.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"541_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0006-2952(96)00463-7","volume":"53","author":"WE M\u00fcller","year":"1997","unstructured":"M\u00fcller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol. 1997;53(2):135\u201340. https:\/\/doi.org\/10.1016\/s0006-2952(96)00463-7.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"541_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0091-3057(94)00254-g","volume":"50","author":"K Scheuer","year":"1995","unstructured":"Scheuer K, Stoll S, Paschke U, Weigel R, M\u00fcller WE. N-Methyl-d-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Biochem Behav. 1995;50(1):65\u201370. https:\/\/doi.org\/10.1016\/0091-3057(94)00254-g.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"541_CR16","first-page":"110","volume":"43","author":"M Moriau","year":"1993","unstructured":"Moriau M, Crasborn L, Lavenne-Pardonge E, et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. 1993;43(2):110\u20138.","journal-title":"Arzneimittelforschung"},{"key":"541_CR17","first-page":"195","volume":"73","author":"H HerrschK","year":"1978","unstructured":"HerrschK H. The eH ect of piracetam on global and regional cerebral blood flow in acute cerebral ischemia of man. Med Klin. 1978;73:195\u2013202.","journal-title":"Med Klin"},{"issue":"1","key":"541_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00002512-199101010-00004","volume":"1","author":"MW Vernon","year":"1991","unstructured":"Vernon MW, Sorkin EM. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging. 1991;1(1):17\u201335. https:\/\/doi.org\/10.2165\/00002512-199101010-00004.","journal-title":"Drugs Aging"},{"issue":"4","key":"541_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/bmc.3579","volume":"30","author":"GD Mendes","year":"2016","unstructured":"Mendes GD, Zaffalon GT, Silveira AS, et al. Assessment of pharmacokinetic interaction between piracetam and l-carnitine in healthy subjects. Biomed Chromatogr. 2016;30(4):536\u201342. https:\/\/doi.org\/10.1002\/bmc.3579.","journal-title":"Biomed Chromatogr"},{"issue":"3","key":"541_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/11319230-000000000-00000","volume":"70","author":"AG Malykh","year":"2010","unstructured":"Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287\u2013312. https:\/\/doi.org\/10.2165\/11319230-000000000-00000.","journal-title":"Drugs"},{"issue":"10","key":"541_CR21","first-page":"1144","volume":"11","author":"Z-T Zhang","year":"2006","unstructured":"Zhang Z-T, Huo Q, Zhao H-Q. Pharmacokinetics and bioequivalence of piracetam tablets in healthy volunteers. Chin J Clin Pharmacol Ther. 2006;11(10):1144\u20137.","journal-title":"Chin J Clin Pharmacol Ther"},{"issue":"17","key":"541_CR22","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","volume":"77","author":"J Deng","year":"2017","unstructured":"Deng J, Zhu X, Chen Z, et al. A review of food-drug interactions on oral drug absorption. Drugs. 2017;77(17):1833\u201355. https:\/\/doi.org\/10.1007\/s40265-017-0832-z.","journal-title":"Drugs"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00541-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:40:39Z","timestamp":1776066039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00541-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00541-0","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LQY is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. HCP is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. WQH is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed abiding by the Declaration of Helsinki, Good Clinical Practice (GCP), and guidelines of the China National Medical Products Administration (NMPA). The protocol, informed consent, and other relevant documents were approved by the independent ethics committee of Wuhan Pulmonary Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants prior to their enrollment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All researchers, participants, institutions and the sponsors have agreed to publish the results of this study in this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed for the current study are available from the corresponding authors upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LG participated in the conception and design and contributed to quality control throughout the study. YHG contributed to the writing of the manuscript. ZM contributed to the study organization and implementation. PY and LXW were in charge of the management of study drugs. PZX, WJ, and XYF were responsible for disposition of biological samples. As the sponsor-affiliated authors, LQY, HCP, and WQH were involved only in study coordination and administrative support. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}